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Infections at Hospitals: (How) Can We Measure It?
J. A. Schouten,1,2,3 M. E. J. L. Hulscher,1 H. Wollersheim,1,3 J. Braspennning,1 B. J. Kullberg,2,3
J. W. M. van der Meer,2,3 and R. P. T. M. Grol1
1Centre for Quality of Care Research, 2Nijmegen University Centre for Infectious Diseases, and 3Department of General Internal Medicine,
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Background. To assess and improve the quality of antibiotic use in patients with community-acquired pneu-
monia (CAP) and acute exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (AECB), a
valid set of quality indicators is required. This set should also be applicable in practice.
Methods. Guidelines and literature were reviewed to derive potential indicators for quality of antibiotic use
in treating hospitalized patients with lower respiratory tract infection (LRTI). To assess the evidence base of each
indicator, a literature review was performed. Grade A recommendations were considered valid. For grade B–D
recommendations, an expert panel performed a consensus procedure on the indicator’s relevance to patient health,
reduction of antimicrobial resistance, and cost containment. To test applicability in practice, feasibility, opportunity
for improvement, reliability, and case-mix stability were determined for a data set of 899 hospitalized patients
with LRTI.
Results. None of the potential indicators from guidelines and literature were supported by grade A evidence.
Nineteen indicators were selected by consensus procedure (12 indicators for CAP and 7 indicators for AECB).
Lack of feasibility and of opportunity for improvement led to the exclusion of 4 indicators. A final set of 15
indicators was defined (9 indicators for CAP and 6 indicators for AECB).
Conclusions. A valid set of quality indicators for antibiotic use in hospitalized patients with LRTI was developed
by combining evidence and expert opinion in a carefully planned procedure. Subjecting indicators to an applicability
test is essential before using them in quality-improvement projects. In our demonstration setting, 4 of the 19
indicators were inapplicable in practice.
Community-acquired lower respiratory tract infection
(LRTI) is a common cause of acute illness in adults.
The spectrum of disease ranges from mild mucosal col-
onization or infection, to acute bronchitis or acute ex-
acerbation of chronic bronchitis or chronic obstructive
pulmonary disease (AECB), to overwhelming paren-
chymal infection in patients with community-acquired
pneumonia (CAP). Antibiotic treatment is rarely in-
dicated for acute bronchitis and is sometimes indicated
for the more severe cases of AECB, but it is always
indicated for CAP. It may be difficult to differentiate
between viral and bacterial LRTI or between bronchitis,
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AECB, and CAP. This may be one of the reasons why
antibiotics are prescribed to more than two-thirds of
patients with LRTI in Europe and the United States. In
view of the worldwide development of antibiotic resis-
tance, this is not a desirable situation [1].
Recommendations for the rational use of antibiotics
in hospitalized patients with LRTI have been formu-
lated in national and international guidelines [2–7].
Guidelines describe, in essence, “the right thing to do.”
They assist in making practitioner and patient decisions
prospectively for specific clinical circumstances. To
make a valid and reliable assessment of current practice
in patients with LRTI, key recommendations from these
guidelines can be translated into measurable ele-
ments—so-called “indicators” [8]. Indicators serve as
measurable elements of practice performance for which
there is evidence or consensus that they can be used to
assess the quality (and, therefore, change in the quality)
of care provided [9].
Several articles have suggested quality indicators for
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the management of CAP, but the results have often varied in
terms of their relevance, scientific soundness, and interpreta-
bility [10]. To our knowledge, no quality indicators have been
suggested for antibiotic use in hospitalized patients with AECB.
Where possible, indicators should be based directly on scientific
evidence. However, like in many fields of medicine, there is
only a limited scientific basis for recommendations regarding
antibiotic use in cases of LRTI [10]. To develop valid quality
indicators, it is necessary to use a systematic procedure that
combines available evidence and expert opinion to assess ad-
ditional aspects of care for which evidence alone is insufficient,
absent, or methodologically weak [11, 12].
Development of valid quality indicators is, however, not
enough. Validity in itself does not guarantee applicability in a
specific setting. To assess applicability, again, a rigorous ap-
proach is required: indicators should be tested on important
clinimetric characteristics, such as feasibility, reliability, oppor-
tunity for improvement, and case-mix stability [13].
In this article, we describe how we systematically developed
a valid set of quality indicators for antibiotic use in hospitalized
patients with LRTI. In addition, we describe a method to assess
their applicability in daily practice. We used our quality-im-
provement project for antibiotic use in LRTI in 8 Dutch hos-
pitals as a test case.
METHODS
A set of indicators was developed in 4 steps. Applicability was
tested in 5 steps. Figure 1 shows a flowchart detailing the steps
involved in developing the indicators and testing their
applicability.
Development of a Valid Set of Indicators
Preselection of potential indicators. Four independent in-
vestigators (J.S., M.H., and 2 guideline experts) preselected key
recommendations from national guidelines [6, 7]. Quality in-
dicators that were published in international guidelines for CAP
[2–5] or in the literature [10, 14–33] were added to the list of
potential indicators (table 1 and table A1 in the Appendix).
For the latter purpose, a literature search was performed (table
2).
Evidence-based assessment of the indicators. Every poten-
tial indicator was investigated to determine the degree of sci-
entific evidence that linked indicator performance to outcome
(i.e., mortality, morbidity, length of hospitalization, and cost-
effectiveness). We started by reviewing whether the source
(guideline or literature) of the potential indicator specified any
references. A search of the PubMed database was then per-
formed using search terms specific to the quality indicator
topic. On the basis of the available literature, all of the potential
indicators were given 1 of 4 grades (A–D) of supporting evi-
dence (table A2 in the Appendix). Potential indicators with
contradictory evidence were excluded, and grade A recom-
mendations were immediately accepted as valid (i.e., evidence-
based) indicators. The remaining indicators (grades B, C, or
D) were tested further in an expert consensus procedure.
Rating and adding procedure by an expert panel. A panel
of 11 opinion leaders in medical microbiology, infectious dis-
eases, respiratory medicine, and quality-of-care medicine were
asked to conduct a consensus procedure for the preselected set
of indicators [11, 34]. In the 2-round consensus procedure, the
panel judged the potential indicators on the basis of 3 criteria:
(1) clinical relevance to the patient health benefit, (2) relevance
to reducing antimicrobial resistance, and (3) relevance to cost-
effectiveness. A 5-category Likert scale was used that varied
from “completely disagree” (category 1) to “completely agree”
(category 5). An extra answer category could be marked if the
expert could not decide about a particular question. A defi-
nition of these constructs was provided in the covering letter.
In the second round, the expert panel had the opportunity to
comment on the proposed indicators and to add or modify
potential indicators for evaluation.
Only indicators with 170% agreement between the experts
on 1 criterion were selected in the first round. Indicators with
170% disagreement on all 3 criteria were rejected [34]. All of
the other indicators, including those added or modified by the
experts, were reevaluated in the second round.
Final set of indicators. The final step in devising the set
of indicators consisted of operationalizing them by defining
numerators and denominators. An algorithm for every indi-
cator revealed how it had been deduced from the available data.
Assessment of Applicability of Quality Indicators in a Specific
Patient Sample
Setting and study population. To test applicability in a spe-
cific setting, feasibility of data collection, reliability, opportunity
for improvement, and case-mix stability were determined in a
demonstration data set (Dutch LRTI quality-improvement pro-
ject). A prospective observational audit was performed at 8
medium-sized hospitals, including both teaching and nonteach-
ing facilities, in the southeastern part of The Netherlands. Pa-
tients with CAP and AECB were selected on the basis of formal
inclusion criteria.
Data collection. During a 6-month period, trained research
assistants made twice-weekly reviews of the charts of all of the
patients admitted to internal medicine and respiratory medicine
hospital wards. All of the relevant patients were followed-up
during their period of hospitalization and until 30 days after
discharge from the hospital. Data were collected from admis-
sion sheets, medical and nursing records, medication charts,
and microbiological and radiological testing reports. After re-
cording data on the preprinted standardized data forms, 2 as-
sistants entered the results into a database.
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Figure 1. Procedural flowchart showing the steps involved in the development of indicators for assessing and improving the quality of antibiotic
use in patients with community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis or chronic obstructive pulmonary disease
(AECB), as well as the steps involved in testing the applicability of those indicators. ATS, American Thoracic Society; BTS, British Thoracic Society;
ERS, European Respiratory Society; IDSA, Infectious Diseases Society of America; QI, quality improvement.
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Table 1. Rating and adding procedure for the development of quality indicators for antibiotic use in lower respiratory tract infection.
Disease, recommendation
Supporting
evidencea
Selection round
First
round
Second
round
CAP
No. of recommendations selected 4 8
1. Initiate antibiotic therapy !4 h after presentation B [22, 38] Selected
2. Include coverage of Legionella species in empirical antibiotic therapy for severe CAP B [44–49] Added Rejected
3. Prescribe empirical antibiotic therapy in adherence with national guidelines B [27, 30, 39] Selected
4. Adapt dose and dose interval of antibiotics to renal function D Added Selected
5. Switch from intravenous to oral antibiotic therapy according to existing criteria and clinical
stability
B [40, 41] No decision Selected
6. Change broad-spectrum empirical therapy to pathogen-directed therapy as soon as culture results
become available
C [3, 6] Selected
7. Stop antibiotic therapy if no fever for 3 days D Added Selected
8. Change antibiotic therapy if no clinical improvement within 72 h of initiation D Added Selected
9. Perform Gram stain and culture of a sputum sample D [3, 6] Selected
10. Perform culture of 2 blood samples B [50, 51] No decision Selected
11. Perform cultures !24 h after presentation B [22] Changed to rec. 12
12. Perform blood cultures !24 h after presentation B [22] Modified from rec. 11 Rejected
13. Perform cultures before empirical therapy B [22] Changed to recs.
14 and 15
14. Perform 2 blood cultures before empirical therapy B [22] Modified from rec. 13 Selected
15. Perform Gram stain and culture of sputum sample before empirical therapy D [6] Modified from rec. 13 Selected
16. Perform serological tests for atypical microorganisms on clinical suspicion D [3, 6] No decision Rejected
17. Perform urine antigen testing against Legionella species on clinical suspicion B [52] Added Selected
Exacerbation of CB or COPD
No. of recommendations selected 4 3
1. Prescribe antibiotic therapy for exacerbation of CB or COPD only when indicated B [53, 54] Selected
2. Do not use macrolide as first choice of antibiotic B [55, 56] Selected
3. Adapt dose and dose interval of antibiotics to renal function D Added Selected
4. Switch from intravenous to oral antibiotic therapy according to existing criteria and clinical
stability
D [7] Selected
5. Change broad-spectrum empirical therapy to pathogen-directed therapy as soon as culture results
become available
D [7] No decision Selected
6. Perform Gram stain and culture of a sputum sample D [7] Selected
7. Optimal duration of antibiotic therapy should be 5–7 days D Added Selected
NOTE. CAP, community-acquired pneumonia; CB, chronic bronchitis; COPD, chronic obstructive pulmonary disease.
a Supporting evidence is rated on a scale of grade A–grade D (see table A2 in the Appendix).
Applicability steps and analysis. Clinimetric characteris-
tics of quality indicators—including feasibility, reliability, op-
portunity for improvement, and case-mix stability—were de-
fined and determined in the demonstration data set. In
addition, factor analysis was performed for data (i.e., indicator)
reduction purposes.
Feasibility. Feasibility of data abstraction was defined as
the percentage of missing values per indicator (i.e., the per-
centage of indicator values that could not be calculated because
1 element of the algorithm could not be retrieved from the
available records). Feasibility was considered poor if this per-
centage exceeded 25%.
Reliability. To assess the reliability of our data collection,
the percentage of agreement between 2 data reviewers on the
level of indicator outcome, corrected for chance, was expressed
in k coefficients. A sample consisting of 10% of the records of
2 hospitals was collected by 2 independent data reviewers.
Scores of were considered to be moderate,0.41 k 0.6
were considered to be good, and were0.61 k 0.8 k 1 0.8
considered to be very good [35]. Values of !0.4 were considered
to be poor and led to elimination of the indicator.
Potential opportunity for quality improvement. Quality
measures must be capable of detecting changes in the quality
of care to discriminate between and within subjects. If indicator
performance is invariably high, with little variation, this renders
an indicator less sensitive and thus less successful as an indi-
cator. From the viewpoint of internal quality improvement,
indicators with a performance score 185% were defined as
having limited room for improvement. Indicators with a per-
formance score 185% in all participating hospitals were not
selected [8, 36].
Case-mix stability. Case-mix stability is an important in-
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Table 2. Summary of a systematic literature search for quality
indicators for antibiotic use in the treatment of community-ac-
quired pneumonia (CAP) and acute exacerbation of chronic bron-
chitis or chronic obstructive pulmonary disease (COPD).
Methods
Medical subject heading terms used were“quality of care,”
“quality,” “performance,” “recommended processes of
care,” “indicators,” “antibiotic use,” “antibiotics” combined
with “community-acquired pneumonia,” “pneumonia,” and
“CAP” or combined with “exacerbation,” “exacerbation
COPD,” and “exacerbation of chronic bronchitis.”
Original peer-reviewed articles were selected between January
1990 and July 2004 from the PubMed database.
Proposed indicators could cover the entire process of care from
admission to discharge, but had to relate in some way to anti-
biotic use. Diagnostic procedures were included as long as
they were likely to influence the use of antibiotics (i.e., choice
of drug, dosage, or duration of therapy).
Excluded articles included all articles with children as study
subjects, articles that did not specifically address CAP or
exacerbation of COPD, articles that did not address antibiotic
use, articles that were letters or case reports, articles that ad-
dressed patients with HIV/AIDS, and articles that only ad-
dressed patient outcome indicators (e.g., mortality and length
of hospitalization).
Results
The initial search yielded 177 articles involving CAP; 156 of
these studies were excluded on the basis of titles and ab-
stracts. Reasons for exclusion were as follows: article did not
specifically address CAP (77 articles); article did not address
indicators or only addressed outcome indicators for CAP (59);
article addressed patients with HIV/AIDS (7); article had chil-
dren as study subjects (6); and article was letter or case re-
port (7). The remaining 21 articles [10, 14–33] were reviewed
for indicators. From these studies, 4 additional potential indi-
cators (i.e., indicators that had not already been derived from
national guidelines) were added to the list. These included ini-
tiation of antibiotic use !4 h after presentation, prescription of
antibiotic therapy in adherence with national guidelines, per-
formance of blood and sputum cultures !24 h after presenta-
tion, and performance of blood and sputum cultures before
empirical therapy.
No relevant articles were found for acute exacerbation of
chronic bronchitis or COPD that provided indicators for antibi-
otic use.
dicator asset, enabling application of an indicator to monitor
quality in a specific hospital over time and to compare hospitals
of different sizes and settings [13]. The relationship between
certain patient characteristics and the indicator result was an-
alyzed to decide whether correction for case mix was necessary.
In the CAP indicators, we studied the distribution of outcome
according to age (either 70 years or !70 years), sex, and
Pneumonia Severity Index [37] (eitherIII or 1III). For AECB,
no validated severity-of-illness score was available, so we used
the most recent forced expiratory volume in 1 second (FEV1)
value (expressed as a percentage of the predicted value) as a
substitute. The need for case-mix correction did not lead to
exclusion from our final set.
Factor analysis. Factor analysis was performed to detect
relationships between indicators, thus potentially leading to a
reduction in the number of indicators [36]. To perform data
reduction through factor analysis, a minimum of correlation
between the items is required. We used Bartlett’s sphericity test
(in which P should be !.05), Kaiser-Maier-Olkin measure of
sampling adequacy (MSA) (in which MSA should be 10.5),
and R2 (in which R2 should be 10.20). This procedure was
performed separately for the sets of CAP and AECB indicators.
RESULTS
Development of a valid set of indicators. In the first step, 10
potential indicators for CAP and 5 for AECB were preselected
from national and international guidelines and the literature
(figure 1 and table 2). No “good supporting evidence” (grade
A) could be found that linked process to outcome in any of
these indicators. None of the indicators had to be excluded
because of contradictory evidence (table 1).
All 15 potential indicators were entered into the iterated
consensus procedure. In the first round, 4 recommendations
were immediately selected for both CAP and AECB. No in-
dicators were eliminated. Six new items (4 for CAP and 2 for
AECB) were added by the expert panel. One potential indicator
was revised, and another was split into 2 separate indicators.
In the second round, 8 potential indicators (5 for CAP and 3
for AECB) out of 14 (11 for CAP and 3 for AECB) remaining
recommendations were selected. The ultimate set was consid-
ered to be valid. It consisted of 12 indicators for CAP and 7
indicators for AECB.
Assessment of applicability of quality indicators in a specific
patient sample. All 19 validated indicators were tested using
a sample of 443 hospitalized patients with CAP and 456 hos-
pitalized patients with AECB (tables 3 and 4). A review was
made of the distribution of performance of the indicators over
the 8 hospitals. Although there was wide variability in outcome
(table 3), this was not because of the patient mix (data not
shown).
Feasibility. Feasibility of 3 indicators was poor in our dem-
onstration data set of Dutch patients with LRTI. Performing
cultures of blood and sputum samples before the first antibiotic
dose was administered showed poor feasibility: 55% of the
subjects had missing values for timely culturing of blood sam-
ples, and 75% had missing values for timely culturing of spu-
tum samples. These 2 indicators were rejected. It proved to be
impossible to construct an algorithm for 1 of the 12 indicators
for CAP (“change antibiotic therapy if no clinical improvement
within 72 h of initiation”). We were unable to operationalize
“no clinical improvement.” This indicator was considered to
be nonfeasible (100% of the subjects had missing values) and
was also rejected.
Reliability. One indicator (timeliness of antibiotic admin-
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Table 3. Applicability of quality indicators for antibiotic use in 443 patients hospitalized with community-acquired pneumonia in 8
Dutch hospitals.
Indicator
Feasibility,
% of patients
with missing
values
Opportunity for
improvement,
% (range)a
Interobserver
reliability, k
Case-mix
correction
Prescribe empirical therapy adherent to national guidelines 0.7 45 (5–59) 0.7 No
Initiate antibiotic therapy within 4 h after presentation 21b 68 (35–87) 0.5 No
Adapt dose and dosing interval of antibiotics to renal function 17 77 (40–100) 1 Yesc
Switch from intravenous to oral antibiotic therapy according to existing
criteria and clinical stability 5 81 (35–93) 0.7 No
Change broad-spectrum empirical therapy to pathogen-directed therapy as
soon as culture results become available 8 80 (50–100) 0.7 No
Change antibiotic therapy if no clinical improvement occurs within 72 h
after initiation 100 NAd NAd NAd
Stop antibiotic therapy 3 days after defervecence 18 11 (0–41) 1 No
Perform Gram stain and culture of a sputum sample 0 54 (20–63) 1 Yese
Perform culture of 2 blood samples 0 57 (48–67) 0.6 Yesc
Perform Gram stain and culture of a sputum sample before empirical
therapy 75 24 (0–100) 0.8 NA
Perform culture of 2 blood samples before empirical therapy 55 85 (70–100) 0.8 NA
Perform a urine antigen test against Legionella species on clinica suspicionl 0 84 (67–100) ND No
NOTE. NA, not applicable; ND, not enough data available.
a Opportunity for improvement is given as the median percentage of patients for whom the indicator was performed per hospital (range).
b Data excludes 1 outlier hospital (see Results).
c Correction for age required.
d No algorithm could be created for this indicator.
e Correction for sex required.
istration) received a score of , indicating moderate in-kp 0.5
terobserver reliability. All other indicators showed k scores of
10.6 (i.e., good or very good). No indicator was rejected.
Opportunity for improvement. The AECB recommendation
to not prescribe macrolides as a first-choice antibiotic showed
a high outcome (performed in 190% of cases) in each partic-
ipating hospital, and thus it showed little room for improve-
ment. This indicator was rejected for use as a quality indicator
in our quality-improvement project. For the AECB indicator
“adapt dose and dose interval to renal function,” there was a
high median performance rate (96%), but an outlier hospital
with a performance rate of 73% of cases was detected, and the
indicator was, therefore, not rejected.
Need for case-mix correction. Two CAP indicators needed
correction for age: “adapting dose and dose interval of anti-
biotics to renal function” ( ) and “obtaining samplesPp .0001
for blood cultures” ( ). Regarding sex, sputum samplesPp .003
were obtained significantly more often from men than from
women ( ). All of the other CAP indicators showedPp .001
stable patterns of distribution over the 3 patient characteristics
(age, sex, and severity of illness). In the population of patients
with AECB, sputum cultures were performed more consistently
in patients with an FEV1 value of 60% ( ). The needPp .033
for case-mix correction did not lead to exclusion from our set
but should be taken into account for interpretation of perfor-
mance scores in our group of hospitals.
Factor analysis. For CAP and AECB, Bartlett’s sphericity
test ( and ), Kaiser-Maier-Olkin MSA (0.463Pp .091 Pp .161
and 0.489), and R2 (0.147 and 0.137) indicated that no relevant
correlation was detected between the indicators. Subsequently,
further factor analysis, performed in an attempt to reduce the
number of indicators, was not considered useful. Our set com-
prises intrinsically strong indicators.
DISCUSSION
On the basis of a carefully planned procedure that combined
evidence and expert opinion, we developed a set of valid quality
indicators for antibiotic use in hospitalized patients with LRTIs.
In addition, we showed the importance of subjecting these
indicators to a practice test before using them to measure and
improve the quality of care in a specific setting. In our example,
only a part of the valid set (15 of 19 indicators) turned out to
be applicable in daily practice.
None of our potential indicators could rely on a firm body
of evidence that linked process to outcome of care. “Timely
administration of antibiotics” and “prescription of an empirical
antibiotic regimen according to current guidelines” were con-
sistently associated with improved survival in patients with
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Table 4. Applicability of quality indicators for antibiotic use in 456 patients hospitalized with acute exacerbation of chronic bronchitis
or chronic obstructive pulmonary disease.
Indicator
Feasibility,
% of patients
with missing
values
Opportunity for
improvement,
% (range)a
Interobserver
reliability, k
Case-mix
correction
Do not use macrolide therapy as first-choice treatment for bronchitis in
exacerbations of chronic obstructive pulmonary disease. 0 97 (91–100) 0.85 NA
Adapt dose and dose interval of antibiotics to renal function 7 97 (73–100) 1 NA
Administer antibiotics only on strict indication 1 50 (18–78) 1 No
Switch from intravenous to oral antibiotic therapy according to existing
criteria and clinical stability 2 79 (15–100) 0.7 No
Change broad-spectrum empirical therapy to pathogen-directed therapy
as soon as culture results become available 0 80 (0–100) 0.7 No
Perform Gram stain and culture of sputum sample 2 51 (11–68) 1 Yesb
Optimal duration of antibiotic therapy should be 5–7 days 3 26 (18–79) 1 No
a Opportunity for improvement is given as the median percentage of patients for whom the indicator was performed per hospital (range).
b Correction for forced expiratory volume in 1 second required.
CAP, but this was only in observational, retrospective studies
[38, 39]. Several prospective interventional trials have dem-
onstrated that early-switch strategies are cost-effective and safe,
but no randomized, controlled trials have yet confirmed these
results [40, 41]. No firm associations were found between out-
come and most of the other suggested indicators. Results from
our expert consensus procedure demonstrated that these non–
evidence-based recommendations may still be regarded as val-
uable by professionals. Changing from broad-spectrum to nar-
row-spectrum therapy once culture results become available
will probably not directly affect short-term outcome for the
individual patient. However, it has a theoretical effect on re-
ducing the development of resistance, and it may thus turn out
to be crucial for the outcome of future patients [42]. Unfor-
tunately, studies that link process indicators with resistance
patterns are confronted with large methodological difficulties,
so it will be difficult to prove any definite relationship. Using
a technique that systematically combined evidence and con-
sensus enabled us to assess (and thus improve) a broader range
of aspects than would have been possible if quality indicators
had been restricted to evidence only.
Even if our set of indicators is considered to be valid, its
applicability in daily practice has several other important pre-
requisites. In our demonstration data set of hospitalized Dutch
patients with LRTI, most of the indicators showed reasonable
applicability (i.e., they were found to be feasible and reliable
and showed room for improvement). Unfortunately, the fea-
sibility of data collection turned out to be poor for some in-
dicators. These findings support our belief that Dutch hospitals
do not have systematic and robust registration systems (e.g.,
for registering the timing of hospital procedures). This currently
constitutes a major barrier against the application of these kinds
of quality indicators in The Netherlands, not only for research
purposes, but also for monitoring the quality of daily practice.
Once Dutch hospitals are required to collect these data—for
example, as part of their normal review process—documen-
tation will probably pick up. Timing of procedures caused ma-
jor feasibility problems in our example, but in other countries,
the feasibility of these indicators may be very different. US
hospitals, for example, readily collect data for antibiotic timing
as part of their normal review and accreditation process. In the
United States, however, other data collection problems may
arise, jeopardizing feasibility. This underlines the importance
of performing an applicability test before using indicators to
measure and improve the quality of care in a specific setting.
In our applicability test, we used a performance rate of 85%
of cases (for each participating hospital) as a cut-off value to
exclude indicators. From the viewpoint of internal quality im-
provement, indicators that score 185% in all hospitals have
little room for improvement. Quality measures must be capable
of detecting changes to discriminate between and within sub-
jects. If indicator performance is invariably high with little in-
terhospital variation, this renders an indicator less sensitive and
thus less successful as an indicator [36]. The main goal of
subjecting our set of indicators to this criterion was to prioritize
the indicators most in need of improvement in a quality-im-
provement project (i.e., those indicators with low performance
rates and/or large interhospital variation). Using “opportunity
for quality improvement” as a selection criterion is particularly
important for internal quality-improvement efforts. If, on the
other hand, the indicator set is to be used for accreditation
purposes, for example, room for improvement might not be
desirable as a selection criterion; the trend in regulating and
accrediting organizations is to provide indicator sets that high-
light excellent performance, as well as merely meet minimal
standards [13].
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Earlier sets of indicators, developed using somewhat different
methodology, show many similarities to our set [10, 24, 43].
In some of these studies, clinimetric criteria, such as feasibility,
reliability, and opportunity for improvement, were appraised
by the clinical judgement of experts [10] and not on the basis
of empirical data from real practice. However, in our experi-
ence, the feasibility of data collection is often overrated by
professionals. All members of our expert panel believed that it
was feasible to measure the time lag between performance of
blood cultures and first antibiotic administration, but in reality,
this could be done for only 25% of patients.
In summary, we developed a robust set of intrinsically strong
indicators using rigorous methodology that combined the avail-
able evidence and expert opinion. Performance assessment in
a practical test showed that some indicators were flawed by
poor feasibility of data collection. Our experience demonstrates
that, before implementation of a theoretically sound set of in-
dicators, a practice test should be performed to assess its ap-
plicability in daily practice.
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APPENDIX
Table A1. International comparison of quality indicators for community-acquired pneumonia (CAP), by group or organization.
Indicator topic Present report
Joint Commision on the Accredita-
tion of Healthcare Organizations
Centers for Medicare
and Medicaid Services
Agency for Healthcare Research
and Quality (National Quality
Measures Clearinghouse)
Antibiotic choice Empirical antibiotic regimen accord-
ing to current national guidelines
Initial antibiotic selection consistent
with current recommendations
Initial antibiotic therapy consistent
with current recommendations
Percentage of immunocompetent
patients with CAP who receive
an initial antibiotic regimen dur-
ing the first 24 h that is consis-
tent with current guidelines
Antibiotic timing Timely initiation of antibiotic ther-
apy (within 4 h after
presentation)
Time from initial hospital arrival to
first dose of antibiotic
Antibiotic timing, percentage of pa-
tients with pneumonia who re-
ceived first dose of antibiotics
within 4 h after hospital arrival
Percentage of patients who re-
ceived their initial dose of antibi-
otics within 4 h of hospital arri-
val; median time from hospital
arrival to administration of first
antibiotic dose
Blood cultures Obtaining 2 sets of blood samples
for culture; culture of 2 blood
samples before empirical therapy
Blood cultures performed prior to
first antibiotic administration
Blood cultures performed prior to
first antibiotic administration
Percentage of patients whose ini-
tial blood culture specimen was
collected prior to the first hospi-
tal dose of antibiotics; percent-
age of patients who had blood
cultures performed within 24 h
prior to or after hospital arrival
Sputum culture Obtaining sputum samples for
Gram stain and culture; obtaining
sputum samples for Gram stain
and culture before administration
of empirical therapy
… … …
Urine antigen test Urine antigen testing against Le-
gionella species on clinical
suspicion
… … …
Oxygenation assessment … Oxygenation assessment within 24
h of hospital arrival
Percentage of patients who re-
ceived an oxygen assessment
within 24 h prior to or after hos-
pital arrival
Percentage of patients who re-
ceived oxygenation assessment
within 24 h prior to or after arri-
val at the hospital
Smoking … Adult CAP smoking cessation
counseling
Smoking cessation advice/
counseling
Percentage of adult patients with a
history of smoking cigarettes
who are given smoking cessa-
tion advice/counseling during
hospital stay
Vaccination … Inpatients screened for and/or
given pneumococcal vaccination
Pneumococcal screening and vacci-
nation; influenza screening/
vaccination
Percentage of Medicare members
aged 65 years who ever re-
ceived a pneumococcal vaccina-
tion; percentage of applicable pa-
tients admitted to the hospital
for pneumonia who received
pneumococcal immunization prior
to admission; percentage of pa-
tients who were screened for
pneumococcal vaccine status
and were vaccinated prior to dis-
charge, if indicated; Percentage
of patients admitted to the hospi-
tal for CAP who received influ-
enza immunization in the preced-
ing influenza period; percentage
of patients who received influ-
enza vaccination
Changing therapy Switching from intravenous to oral
therapy, according to existing cri-
teria and when clinically stable;
changing broad-spectrum empiri-
cal therapy into pathogen-di-
rected therapy (streamlining ther-
apy); adapting dose and dose
interval of antibiotics to renal
function; stopping antibiotic ther-
apy after 3 consecutive days of
defervescence
Appropriate timing of intravenous
to oral antibiotic switcha; exces-
sive antibiotic usea
… …
Patient outcome … Risk-adjusted pneumonia mortality
ratea
… Pneumonia mortality rate; bacterial
pneumonia hospital admission
rate
a Recommended for future core measure completion by the Joint Commision on the Accreditation of Healthcare Organizations.
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Table A2. Level of supporting evidence linking indicator performance to outcome.
Evidence
level Definition
Example of a study providing
the specified level of evidence
A1 A good systematic review of studies designed to answer
the question of interest
Systematic review of randomized, controlled trials
A2 One or more rigorous studies designed to answer the
question but not formally combined
Randomized, controlled trial
B One or more prospective clinical studies that illuminate but
do not rigorously answer the question
Prospective cohort study; underpowered or poor quality ran-
domized, controlled trial; nonrandomized, controlled trial
C One or more retrospective clinical studies that illuminate
but do not rigorously answer the question
Audit or retrospective case-control study
D Formal combination of expert views or other information Delphi study; expert opinion; informal consensus
NOTE. From [57].
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